The Rheumatology Drugs for COVID-19 Management: Which and When?

Introduction: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, and...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Med
Auteurs principaux: Atzeni, Fabiola, Masala, Ignazio Francesco, Rodríguez-Carrio, Javier, Ríos-Garcés, Roberto, Gerratana, Elisabetta, La Corte, Laura, Giallanza, Manuela, Nucera, Valeria, Riva, Agostino, Espinosa, Gerard, Cervera, Ricard
Format: Artigo
Langue:Inglês
Publié: MDPI 2021
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7919806/
https://ncbi.nlm.nih.gov/pubmed/33669218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10040783
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires